Effects of nutritional supplements on antibody levels in pregnant

women vaccinated with inactivated SARS-CoV-2 vaccines

4 Short Title: Effects of nutritional supplements on antibody levels in pregnant

5 women

1

2

3

6

9

18

23

24

25

2627

28

- 7 Xi Zhang, MPH¹, Xue Han, MPH¹, Baolan Chen, MPH¹, Xi Fu, MD¹, Yajie Gong,
- 8 MD^{2,*}, Wenhan Yang, MD^{3,*}, Qingsong Chen, MD^{1,*}
- 10 Department of Occupational and Environmental Health, School of Public Health,
- Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, 510006,
- 12 China
- ² Department of Epidemiology and Medical Statistics, School of Public Health,
- Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, 510006,
- 15 China
- ³ Department of Child and Adolescent Health, School of Public Health, Guangdong
- 17 Pharmaceutical University, Guangzhou, Guangdong Province, 510006, China

19 *Corresponding Author:

- 20 1.Qingsong Chen, E-mail: qingsongchen@aliyun.com,
- 2. Wenhan Yang , E-mail: wenhan-yang@gdpu.edu.cn
- 22 3. Yajie Gong, E-mail: gongyajie2016@163.com

Abstract

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Background: Because of the significantly higher demand for nutrients during pregnancy, pregnant women are more likely to have nutrient deficiencies, which may adversely affect maternal and fetal health. The effect of nutritional supplements on the immune effects of inactivated SARS-CoV-2 vaccines during pregnancy is not clear. **Methods:** In a multicenter cross-sectional study, we enrolled 873 pregnant women aged 18-45 v in Guangdong, China. The general demographic characteristics of pregnant women and their use of nutritional supplements were investigated, and the serum antibody levels induced by inactivated SARS-CoV-2 vaccines were measured. A logistic regression model was used to analyze the association between nutritional supplements and SARS-CoV-2 antibody levels. Results: Of the 873 pregnant women enrolled, 825 (94.5%) took folic acid during pregnancy, 165 (18.9%) took iron supplements, and 197 (22.6%) took DHA. All pregnant women received at least one dose of inactivated SARS-CoV-2 vaccine, and the positive rates of serum SARS-CoV-2 neutralizing antibodies (NAbs) and immunoglobulin G (IgG) antibodies were 44.7% and 46.4%, respectively. After adjustment for confounding factors, whether pregnant women took folic acid, iron supplements, or DHA did not influence NAb positivity or IgG positivity (P > 0.05). Compared with pregnant women who did not take folic acid, the odds ratios (ORs) for the presence of SARS-CoV-2 NAb and IgG antibody in pregnant women who took folic acid were 0.69 (P = 0.282; 95% CI, 0.35-1.35) and 1.31 (P = 0.456; 95% CI, 0.64-2.67), respectively. Compared with pregnant women who did not take iron supplements,

the ORs for the presence of NAb and IgG antibody in pregnant women who took iron supplements were 1.22 (P = 0.336; 95% CI, 0.81-1.84) and 1.01 (P = 0.956; 95% CI, 0.66-1.54), respectively. Similarly, the ORs for NAb and IgG antibody were 0.74 (P =0.125; 95% CI, 0.51-1.08) and 0.97 (P = 0.881; 95% CI, 0.66-1.44) in pregnant women who took DHA compared with those who did not. Conclusions: Nutritional supplementation with folic acid, iron, or DHA during pregnancy was not associated with antibody levels in pregnant women who received inactivated SARS-CoV-2 vaccines.

1 Introduction

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

Since the outbreak of COVID-19, research and development of vaccines and various antiviral drugs to combat COVID-19 and its complications have increased worldwide¹⁻⁴. At present, dozens of COVID-19 vaccines have been approved for use around the world. Because pregnant women have not been included in any clinical trials of COVID-19 vaccines^{5,6}, data on the efficacy and safety of these vaccines for pregnant women are limited. In addition, pregnant women have a significantly higher risk of COVID-19 infection, severe disease, and death due to changes in their immune response during pregnancy⁷⁻⁹. Therefore, it is necessary to understand the risks faced by pregnant women and the associated protective factors. Adequate nutrition is essential to ensure the development, operation, and maintenance of the immune system, and nutritional supplements play an important role¹⁰⁻¹². When malnutrition occurs, the immune response is affected, making the body susceptible to infection, which in turn exacerbates malnutrition. Excessive nutrient intake can adversely affect on all components of the immune system. Therefore, a wellbalanced diet that includes plenty of nutrient-rich foods and supplements is necessary to prevent infectious diseases and ensure optimal immune function^{12,13}. Some studies have shown that nutrient supplements are particularly important during pregnancy. For example, folic acid is an indispensable nutrient during pregnancy, crucial in preventing neural tube defects¹⁴. In addition, folic acid supplementation during pregnancy has been found to reduce the risk of preeclampsia and preterm birth¹⁵. Iron supplements are also necessary during pregnancy. Iron is an essential trace

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

element for the human body. It supports hemoglobin synthesis and is used in the formation of iron-containing enzymes. It also constitutes the body's iron storage in the form of ferritin^{16,17}. Iron deficiency anemia is one of the most common complications of pregnancy and a risk factor for excessive bleeding during childbirth, premature birth, and low birth weight^{18,19}. Pregnant women with iron deficiency anemia are more susceptible to SARS-CoV-2 infection. DHA is an important component of brain cell membranes and is essential for fetal brain development. DHA supplementation during pregnancy promotes fetal brain development and plays an important role in increasing fetal intelligence and improving vision^{20,21}. The World Health Organization recommends that pregnant women should supplement with at least 300mg of DHA per day. Because of its immunomodulatory effects, DHA supplementation during pregnancy can also improve the immune health of the fetus. Nutritional status during pregnancy is crucial. Many nutrients have potent immunomodulatory effects that can modify susceptibility to COVID-19 infection. It is worth exploring whether nutritional supplements can increase the immune response to COVID-19 vaccines. Therefore, the purpose of this study was to investigate the effect of dietary supplements on antibody levels in pregnant women vaccinated with inactivated SARS-CoV-2 vaccine. 2 Materials and Methods

2.1 Study design and inclusion criteria

This multicenter study was performed in the obstetric clinics of three hospitals in

Guangdong Province, China from December 2021 to July 2022. Inclusion criteria included (1) receiving at least one dose of inactivated vaccine before or during pregnancy, (2) being pregnant and having not been infected with COVID-19, and (3) agreeing to participate and providing informed consent. Pregnant women who were infected with COVID-19 after enrollment and were vaccinated with noninactivated COVID-19 vaccines were excluded. A total of 873 pregnant women met the inclusion criteria. The study was approved by the Medical Ethics Review Board of the School of Public Health, Guangdong Pharmaceutical University (IRB 2021-01), and complied with the Declaration of Helsinki guidelines. All participants signed paper informed consent form and minors were excluded from this study.

2.2 Study variable

We developed a survey questionnaire for pregnant women that included questions such as age (stratified by advanced maternal age as defined by the World Health Organization), body mass index(BMI), gravidity and parity, smoking, doses of vaccine taken, adverse events after vaccination, time since vaccination (defined as the time interval between the last dose of vaccine and blood collection), and other general demographic information, vaccination-related information, and information on the types of nutritional supplements used. Vaccination information was collected through the vaccination registration platform.

2.3 Sample collection and analysis

After enrollment, 5 mL of venous blood was collected, centrifuged to separate the serum, and stored in a -80°C freezer. Neutralizing antibody (NAb) levels were

determined via a cytopathogenic effect assay. Specifically, serum samples were inactivated at 56°C for 30 min, diluted fourfold, and incubated with an equal volume (50 μ L) of live SARS-CoV-2 virus suspension at 36.5°C in 5% CO₂ for 2 h. Vero cells (1.0–2.0 \times 10⁵ cells/mL) were then added to the serum–virus suspension in the microplates and incubated in duplicate at 36.5°C in 5% CO₂ for 5 d. Cytopathological effects were observed under the microscope. A NAb titer of <1:8 was considered negative and \geq 1:8 was considered positive. SARS-CoV-2 immunoglobulin G (IgG) antibody was detected by chemiluminescence (Bioscience, Chongqing, China). An antibody level of <1.00 signal to cutoff ratio was considered negative, and a level of \geq 1.00 was considered positive.

2.4 Statistical analysis

Statistical analysis was performed in IBM SPSS version 25 (SPSS Inc., IBM Corp., Armonk, NY). We analyzed demographic data, vaccination-related information, and antibody-positive rates of pregnant women according to whether they were taking nutritional supplements. Chi-squared and Fisher tests were used to compare proportions. Mann–Whitney U-test and Kruskal–Wallis test were used for nonnormal data. A logistic regression model was used to analyze the association between nutritional supplements and SARS-CoV-2 antibody positive rate. All *P*-values were two-sided, and differences with *P*-values <0.05 were considered statistically significant.

3 Results

3.1 Demographics of the study population

Of the 873 pregnant women included in the study, 825 (94.5%) took folic acid, 165 (18.9%) took iron supplements, and 197 (22.6%) took DHA during pregnancy. All pregnant women received at least one dose of inactivated SARS-CoV-2 vaccine, and the positive rates of serum SARS-CoV-2 NAbs and IgG antibodies were 44.7% and 46.4%, respectively. Of the women included in the study 87.9% were <35 years old. Basic demographic characteristics are presented in Tables 1 and 2.

 Table 1
 Demographic characteristics of the participants stratified by type of nutrient supplements.

	T. 4 1	Folio	c acid		Iron sup	plements		Γ	OHA	
Characteristics	Total	Take	No take	_ 	Take	No take	P	Take	No take	P
	(N=873)	(N=825)	(N=48)		(N=165)	(N=708)		(N=197)	(N=676)	
Age group, y				0.054			0.270			0.117
<35	768 (87.9)	730 (88.5)	38 (79.2)		141 (85.5)	627 (88.6)		167 (84.8)	601 (88.9)	
≥35	105 (12.1)	95 (11.5)	10 (20.8)		24 (14.5)	81 (11.4)		30 (15.2)	75 (11.1)	
\mathbf{BMI}^a				0.118			0.846			0.832
<18.5	168 (19.2)	160 (19.4)	8 (16.7)		30 (18.2)	138 (19.5)		35 (17.8)	133 (19.7)	
18.5-24	533 (61.1)	508 (61.6)	25 (52.1)		104 (63.0)	429 (60.6)		122 (61.9)	411 (60.8)	
24-28	137 (15.7)	128 (15.5)	9 (18.7)		24 (14.5)	113 (16.0)		31 (15.7)	106 (15.7)	
≥28	35 (4.0)	29 (3.5)	6 (12.5)		7 (4.2)	28 (3.9)		9 (4.6)	26 (3.8)	
Gravidity				0.002*			0.923			0.169
1	357 (40.9)	345 (41.8)	12 (25.0)		68 (41.2)	289 (40.8)		85 (43.1)	272 (40.2)	
2	337 (38.6)	320 (38.8)	17 (35.4)		65 (39.4)	272 (38.4)		81 (41.1)	256 (37.9)	
≥3	179 (20.5)	160 (19.4)	19 (39.6)		32 (19.4)	147 (20.8)		31 (15.7)	148 (21.9)	
Birth				0.012*			0.870			0.377
0	423 (48.5)	405 (49.1)	18 (37.5)		77 (46.7)	346 (48.9)		94 (47.7)	329 (48.7)	
1	335 (38.4)	318 (38.5)	17 (35.4)		66 (40.0)	269 (38.0)		82 (41.6)	253 (37.4)	
≥2	115 (13.1)	102 (12.4)	13 (27.1)		22 (13.3)	93 (13.1)		21 (10.7)	94 (13.9)	
Education				0.008*			0.381			0.077
Middle school and below	219 (25.1)	198 (24.0)	21 (43.8)		40 (24.2)	179 (25.3)		39 (19.8)	180 (26.6)	
High school	187 (21.4)	176 (21.3)	11 (22.9)		38 (23.0)	149 (21.0)		43 (21.8)	144 (21.3)	
Junior college	294 (33.7)	286 (34.7)	8 (16.7)		48 (29.1)	246 (34.7)		65 (33.0)	229 (33.9)	
Bachelor and above	173 (19.8)	165 (20.0)	8 (16.7)		39 (23.6)	134 (18.9)		50 (25.4)	123 (18.2)	

181 **Table 1 (Continued)**

	7D 4 1	Folio	e acid		Iron sup	plements		DHA		
Characteristics	Total	Take	No take	P	Take	No take	P	Take	No take	P
	(N=873)	(N=825)	(N=48)		(N=165)	(N=708)		(N=197)	(N=676)	
Household income per				0.061			0.947			0.076
capita, m				0.061			0.847			0.076
<4000	139 (15.9)	129 (15.6)	10 (20.8)		23 (13.9)	116 (16.4)		23 (11.7)	116 (17.2)	
4000~6000	269 (30.8)	248 (30.1)	21 (43.8)		50 (30.3)	219 (30.9)		57 (28.9)	212 (31.4)	
6000~10000	298 (34.1)	285 (34.5)	13 (27.1)		58 (35.2)	240 (33.9)		69 (35.0)	229 (33.9)	
≥10000	167 (19.2)	163 (19.8)	4 (8.3)		34 (20.6)	133 (18.8)		48 (24.4)	119 (17.6)	
Smoking				0.067			0.008*			0.017*
No	865 (99.1)	819 (99.3)	46 (95.8)		160 (97.0)	705 (99.6)		192 (97.5)	673 (99.6)	
Yes	8 (0.9)	6 (0.7)	2 (4.2)		5 (3.0)	3 (0.4)		5 (2.5)	3 (0.4)	
Number of exercises per				0.000			-0.001*			0.021*
week				0.999			<0.001*			0.021*
0	330 (37.8)	312 (37.8)	18 (37.5)		39 (23.6)	291 (41.1)		59 (29.9)	271 (40.1)	
<3	55 (6.3)	52 (6.3)	3 (6.3)		9 (5.5)	46 (6.5)		11 (5.6)	44 (6.5)	
≥ 3	488 (55.9)	461 (55.9)	27 (56.3)		117 (70.9)	371 (52.4)		127 (64.5)	361 (53.4)	

a: Since the simple with BMI≥28 was small, it was combined with the simple with 24≤BMI<28 for statistical analysis.

^{183 *:} *P* < 0.05

Table 2 Vaccination and SARS-CoV-2 antibody positivity rates stratified by type of nutrient supplements.

	7D 4 1	Folio	e acid		Iron sup	plements		DHA		
Characteristics	Total	Take	No take	_ 	Take	No take	P	Take	No take	P
	(N=873)	(N=825)	(N=48)		(N=165)	(N=708)		(N=197)	(N=676)	
Doses of vaccination				0.901			<0.001*			<0.001*
One dose	84 (9.6)	79 (9.6)	5 (10.4)		41 (24.8)	43 (6.1)		30 (15.2)	54 (8.0)	
Two doses	669 (76.7)	633 (76.7)	36 (75.0)		114 (69.1)	555 (78.4)		154 (78.2)	515 (76.2)	
Three doses	120 (13.7)	113 (13.7)	7 (14.6)		10 (6.1)	110 (15.5)		13 (6.6)	107 (15.8)	
Adverse events				0.207			0.621			0.825
No	477 (54.6)	455 (55.2)	22 (45.8)		93 (56.4)	384 (54.2)		109 (55.3)	368 (54.4)	
Yes	396 (45.4)	370 (44.8)	26 (54.2)		72 (43.6)	324 (45.8)		88 (44.7)	308 (45.6)	
Inoculation durations,				0.006			-0.001*			0.001*
wk				0.096			<0.001*			0.001*
<20	119 (13.6)	109 (13.2)	10 (20.8)		5 (3.0)	114 (16.1)		8 (4.1)	111 (16.4)	
20-24	107 (12.3)	98 (11.9)	9 (18.8)		10 (6.1)	97 (13.7)		22 (11.2)	85 (12.6)	
24-28	202 (23.1)	188 (22.8)	14 (29.2)		30 (18.2)	172 (24.3)		50 (25.4)	152 (22.5)	
28-32	230 (26.3)	221 (26.8)	9 (18.8)		53 (32.1)	177 (25.0)		61 (31.0)	169 (25.0)	
32-36	138 (15.8)	133 (16.1)	5 (10.4)		48 (29.1)	90 (12.7)		38 (19.3)	100 (14.8)	
≥36	77 (8.9)	76 (9.2)	1 (2.1)		19 (11.5)	58 (8.2)		18 (9.1)	59 (8.7)	
Neutralizing Antibody				0.288			0.017*			<0.001*
+	390 (44.7)	365 (44.2)	25 (52.1)		60 (36.4)	330 (46.6)		66 (33.5)	324 (47.9)	
-	483 (55.3)	460 (55.8)	23 (47.9)		105 (63.6)	378 (53.4)		131 (66.5)	352 (52.1)	
SARS-CoV-2 IgG				0.706			<0.001*			0.012*
+	405 (46.4)	384 (46.5)	21 (43.8)		56 (33.9)	349 (49.3)		76 (38.6)	329 (48.7)	
-	468 (53.6)	441 (53.5)	27 (56.3)		109 (66.1)	359 (50.7)		121 (61.4)	347 (51.3)	

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

We found significant differences in gravidity (P = 0.002), parity (P = 0.012), and education (P = 0.008) according to whether the pregnant women took folic acid. The percentage of pregnant women taking folic acid was higher in those with fewer than two pregnancies (80.6%), ≤ 1 birth (87.6%), and junior college education (34.7%). There were statistically significant differences in smoking (P = 0.008), weekly exercise frequency (P < 0.001), vaccine doses (P < 0.001), time since vaccination (P < 0.001), SARS-CoV-2 neutralizing antibody (P = 0.017), and IgG antibody (P < 0.001) according to whether participants were taking iron supplements. The presence or absence of DHA supplementation was similar to the presence or absence of iron supplementation. There were significant differences between groups in smoking (P =0.017), weekly exercise frequency (P = 0.021), vaccine doses (P < 0.001), time since vaccination (P = 0.001), SARS-CoV-2 neutralizing antibody (P < 0.001), and IgG antibody (P = 0.012). There were no statistically significant differences in age, body mass index, per capita monthly income, or adverse events. We further analyzed the general demographic characteristics of the pregnant women taking the three nutritional supplements separately. For pregnant women who took folic acid, the positive rate of SARS-CoV-2 neutralizing antibody varied significantly with vaccine doses (P < 0.001) and time since vaccination (P < 0.001). The positive rate of IgG antibody varied significantly with age (P = 0.025), adverse events (P = 0.027), vaccine doses (P < 0.001), and time since vaccination (P < 0.001). Among pregnant women who took iron, the positive rates of neutralizing antibody and IgG antibody varied significantly with vaccine doses (P < 0.001). In pregnant women

taking DHA, the difference in the positive rate of IgG antibody between the groups varied significantly with gravidity (P = 0.040), vaccine doses (P < 0.001), and time since vaccination (P < 0.001). The positive rate of NAbs varied significantly with vaccine doses (P < 0.001) and time since vaccination (P = 0.009) (see Tables 3–5).

230 Table 3 Demographic characteristics of the participants taking folic acid.

	Т.4.1	Neutralizi	ng Antibody		I	gG	
Characteristics	Total	+	-	P	+	-	P
	(N=825)	(N=365)	(N=460)		(N=384)	(N=441)	
Age group, y				0.185			0.025*
<35	730 (88.5)	329 (90.1)	401 (87.2)		350 (91.1)	380 (86.2)	
≥35	95 (11.5)	36 (9.9)	59 (12.8)		34 (8.9)	61 (13.8)	
\mathbf{BMI}^a				0.983			0.419
<18.5	160 (19.4)	70 (19.2)	90 (19.6)		68 (17.7)	92 (20.9)	
18.5-24	508 (61.6)	226 (61.9)	282 (61.3)		245 (63.8)	263 (59.6)	
24-28	128 (15.5)	51 (14.0)	77 (16.7)		55 (14.3)	73 (16.6)	
≥28	29 (3.5)	18 (4.9)	11 (2.4)		16 (4.2)	13 (2.9)	
Gravidity				0.734			0.411
1	345 (41.8)	158 (43.3)	187 (40.7)		170 (44.3)	175 (39.7)	
2	320 (38.8)	137 (37.5)	183 (39.8)		143 (37.2)	177 (40.1)	
≥3	160 (19.4)	70 (19.2)	90 (19.6)		71 (18.5)	89 (20.2)	
Birth				0.920			0.572
0	405 (49.1)	182 (49.9)	223 (48.5)		196 (51.0)	209 (47.4)	
1	318 (38.5)	139 (38.1)	179 (38.9)		143 (37.2)	175 (39.7)	
≥2	102 (12.4)	44 (12.1)	58 (12.6)		45 (11.7)	57 (12.9)	
Education				0.829			0.909
Middle school and below	198 (24.0)	86 (23.6)	112 (24.3)		91 (23.7)	107 (24.3)	
High school	176 (21.3)	83 (22.7)	93 (20.2)		86 (22.4)	90 (20.4)	
Junior college	286 (34.7)	126 (34.5)	160 (34.8)		130 (33.9)	156 (35.4)	
Bachelor and above	165 (20.0)	70 (19.2)	95 (20.7)		77 (20.1)	88 (20.0)	
Household income per				0.097			0.266
capita, m				0.097			0.200
<4000	129 (15.6)	57 (15.6)	72 (15.7)		65 (16.9)	64 (14.5)	
4000~6000	248 (30.1)	111 (30.4)	137 (29.8)		119 (31.0)	129 (29.3)	
6000~10000	285 (34.5)	138 (37.8)	147 (32.0)		135 (35.2)	150 (34.0)	
≥10000	163 (19.8)	59 (16.2)	104 (22.6)		65 (16.9)	98 (22.2)	
Smoking				1.000			1.000
No	819 (99.3)	362 (99.2)	457 (99.3)		381 (99.2)	438 (99.3)	
Yes	6 (0.7)	3 (0.8)	3 (0.7)		3 (0.8)	3 (0.7)	
Number of exercises per				0.285			0.652
week				0.283			0.032
0	312 (37.8)	149 (40.8)	163 (35.4)		151 (39.3)	161 (36.5)	
<3	52 (6.3)	22 (6.0)	30 (6.5)		25 (6.5)	27 (6.1)	
≥3	461 (55.9)	194 (53.2)	267 (58.0)		208 (54.2)	253 (57.4)	
Adverse events				0.111			0.027*
No	455 (55.2)	190 (52.1)	265 (57.6)		196 (51.0)	259 (58.7)	
Yes	370 (44.8)	175 (47.9)	195 (42.4)		188 (49.0)	182 (41.3)	

232 Table 3 (Continued)

	T 1	Neutralizii	ng Antibody		I	gG	
Characteristics	Total (N=825)	+	-	P	+	-	P
	(N=825)	(N=365)	(N=460)		(N=384)	(N=441)	
Doses of vaccination				<0.001*			<0.001*
One dose	79 (9.6)	5 (1.4)	74 (16.1)		5 (1.3)	74 (16.8)	
Two doses	633 (76.7)	248 (67.9)	385 (83.7)		266 (69.3)	367 (83.2)	
Three doses	113 (13.7)	112 (30.7)	1 (0.2)		113 (29.4)	0 (0.0)	
Inoculation durations, wk				<0.001*			<0.001*
<20	109 (13.2)	88 (24.1)	21 (4.6)		97 (25.3)	12 (2.7)	
20-24	98 (11.9)	47 (12.9)	51 (11.1)		53 (13.8)	45 (10.2)	
24-28	188 (22.8)	86 (23.6)	102 (22.2)		84 (21.9)	104 (23.6)	
28-32	221 (26.8)	73 (20.0)	148 (32.2)		83 (21.6)	138 (31.3)	
32-36	133 (16.1)	44 (12.1)	89 (19.3)		44 (11.5)	89 (20.2)	
≥36	76 (9.2)	27 (7.4)	49 (10.7)		23 (6.0)	53 (12.0)	

233 *: *P* < 0.05

234 Table 4 Demographic characteristics of the participants taking iron supplements.

	TF 4 1	Neutralizi	ng Antibody		I	gG	
Characteristics	Total	+	-	P	+	-	
	(N=165)	(N=60)	(N=105)		(N=56)	(N=109)	
Age group, y				0.900			0.593
<35	141 (85.5)	51 (85.0)	90 (85.7)		49 (87.5)	92 (84.4)	
≥35	24 (14.5)	9 (15.0)	15 (14.3)		7 (12.5)	17 (15.6)	
\mathbf{BMI}^a				0.096			0.300
<18.5	30 (18.2)	6 (10.0)	24 (22.9)		7 (12.5)	23 (21.1)	
18.5-24	104 (63.0)	40 (66.7)	64 (61.0)		36 (64.3)	68 (62.4)	
24-28	24 (14.5)	11 (18.3)	13 (12.4)		11 (19.6)	13 (11.9)	
≥28	7 (4.3)	3 (5.0)	4 (3.8)		2 (3.6)	5 (4.6)	
Gravidity				0.665			0.628
1	68 (41.2)	26 (43.3)	42 (40.0)		23 (41.1)	45 (41.3)	
2	65 (39.4)	21 (35.0)	44 (41.9)		20 (35.7)	45 (41.3)	
≥3	32 (19.4)	13 (21.7)	19 (18.1)		13 (23.2)	19 (17.4)	
Birth				0.489			0.966
0	77 (46.7)	29 (48.3)	48 (45.7)		26 (46.4)	51 (46.8)	
1	66 (40.0)	21 (35.0)	45 (42.9)		22 (39.3)	44 (40.4)	
≥2	22 (13.3)	10 (16.7)	12 (11.4)		8 (14.3)	14 (12.8)	
Education				0.537			0.723
Middle school and below	40 (24.2)	16 (26.7)	24 (22.9)		15 (26.8)	25 (22.9)	
High school	38 (23.0)	10 (16.7)	28 (26.7)		10 (17.9)	28 (25.7)	
Junior college	48 (29.1)	19 (31.7)	29 (27.6)		17 (30.4)	31 (28.4)	
Bachelor and above	39 (23.6)	15 (25.0)	24 (22.9)		14 (25.0)	25 (22.9)	
Household income per				0.101			0.262
capita, m				0.181			0.363
<4000	23 (13.9)	6 (10.0)	17 (16.2)		5 (8.9)	18 (16.5)	
4000~6000	50 (30.3)	14 (23.3)	36 (34.3)		16 (28.6)	34 (31.2)	
6000~10000	58 (35.2)	24 (40.0)	34 (32.4)		20 (35.7)	38 (34.9)	
≥10000	34 (20.6)	16 (26.7)	18 (17.1)		15 (26.8)	19 (17.4)	
Smoking				0.355			0.211
No	160 (97.0)	57 (95.0)	103 (98.1)		53 (94.6)	107 (98.2)	
Yes	5 (3.0)	3 (5.0)	2 (1.9)		3 (5.4)	2 (1.8)	
Number of exercises per				0.010			0.514
week				0.918			0.514
0	39 (23.6)	13 (21.7)	26 (24.8)		11 (19.6)	28 (25.7)	
<3	9 (5.5)	3 (5.0)	6 (5.7)		2 (3.6)	7 (6.4)	
≥3	117 (70.9)	44 (73.3)	73 (69.5)		43 (76.8)	74 (67.9)	
Adverse events				0.358			0.604
No	93 (56.4)	31 (51.7)	62 (59.0)		30 (53.6)	63 (57.8)	
Yes	72 (43.6)	29 (48.3)	43 (41.0)		26 (46.4)	46 (42.2)	
225							

236 Table 4 (Continued)

	T-4-1	Neutralizi	ng Antibody		I		
Characteristics	Total (N=165)	+	-	P	+	-	P
	(N=165)	(N=60)	(N=105)		(N=56)	(N=109)	
Doses of vaccination				<0.001*			<0.001*
One dose	41 (24.8)	3 (5.0)	38 (36.2)		2 (3.6)	39 (35.8)	
Two doses	114 (69.1)	47 (78.3)	67 (63.8)		44 (78.6)	70 (64.2)	
Three doses	10 (6.1)	10 (16.7)	0 (0.0)		10 (17.9)	0 (0.0)	
Inoculation durations, wk				0.063			0.208
<20	5 (3.0)	4 (6.7)	1 (1.0)		4 (7.1)	1 (0.9)	
20-24	10 (6.1)	3 (5.0)	7 (6.7)		5 (8.9)	5 (4.6)	
24-28	30 (18.2)	15 (25.0)	15 (14.3)		11 (19.6)	19 (17.4)	
28-32	53 (32.1)	14 (23.3)	39 (37.1)		14 (25.0)	39 (35.8)	
32-36	48 (29.1)	15 (25.0)	33 (31.4)		16 (28.6)	32 (29.4)	
≥36	19 (11.5)	9 (15.0)	10 (9.5)		6 (10.7)	13 (11.9)	

237 *: *P* < 0.05

Table 5 Demographic characteristics of the participants taking DHA.

	7D 4 1	Neutralizi	ng Antibody]	[gG	
Characteristics	Total	+	-	P	+	-	P
	(N=197)	(N=66)	(N=131)		(N=76)	(N=121)	
Age group, y				0.690			0.294
<35	167 (84.8)	55 (83.3)	112 (85.5)		67 (88.2)	100 (82.6)	
≥35	30 (15.2)	11 (16.7)	19 (14.5)		9 (11.8)	21 (17.4)	
\mathbf{BMI}^a				0.826			0.975
<18.5	35 (17.8)	11 (16.7)	24 (18.3)		14 (18.4)	21 (17.4)	
18.5-24	122 (61.9)	40 (60.6)	82 (62.6)		47 (61.8)	75 (62.0)	
24-28	31 (15.7)	11 (16.7)	20 (15.3)		11 (14.4)	20 (16.6)	
≥28	9 (4.6)	4 (6.0)	5 (3.8)		4 (5.3)	5 (4.1)	
Gravidity				0.461			0.040*
1	85 (43.1)	29 (43.9)	56 (42.7)		35 (46.1)	50 (41.3)	
2	81 (41.1)	24 (36.4)	57 (43.5)		24 (31.6)	57 (471.)	
≥3	31 (15.7)	13 (19.7)	18 (13.7)		17 (22.4)	14 (11.6)	
Birth				0.620			0.231
0	94 (47.7)	31 (47.0)	63 (48.1)		38 (50.0)	56 (46.3)	
1	82 (41.6)	26 (39.4)	56 (42.7)		27 (35.5)	55 (45.5)	
≥2	21 (10.7)	9 (13.6)	12 (9.2)		11 (14.5)	10 (8.3)	
Education				0.786			0.734
Middle school and below	39 (19.8)	13 (19.7)	26 (19.8)		15 (19.7)	24 (19.8)	
High school	43 (21.8)	12 (18.2)	31 (23.7)		14 (18.4)	29 (24.0)	
Junior college	65 (33.0)	22 (33.3)	43 (32.8)		25 (32.9)	40 (33.1)	
Bachelor and above	50 (25.4)	19 (28.8)	31 (23.7)		22 (28.9)	28 (23.1)	
Household income per				0.582			0.696
capita, m				0.382			0.090
<4000	23 (11.7)	6 (9.1)	17 (13.0)		11 (14.5)	12 (9.9)	
4000~6000	57 (28.9)	19 (28.8)	38 (29.0)		20 (26.3)	37 (30.6)	
6000~10000	69 (35.0)	27 (40.9)	42 (32.1)		28 (36.8)	41 (33.9)	
≥10000	48 (24.4)	14 (21.1)	34 (26.0)		17 (22.4)	31 (25.6)	
Smoking				1.000			1.000
No	192 (97.5)	64 (97.0)	128 (97.7)		74 (97.4)	118 (97.5)	
Yes	5 (2.5)	2 (3.0)	3 (2.3)		2 (2.6)	3 (2.5)	
Number of exercises per				0.710			0.312
week				0.710			0.312
0	59 (29.9)	19 (28.8)	40 (30.5)		19 (25.0)	40 (33.1)	
<3	11 (5.6)	5 (7.6)	6 (4.6)		6 (7.9)	5 (4.1)	
≥3	127 (64.5)	42 (63.6)	85 (64.9)		51 (67.1)	76 (62.8)	
Adverse events				0.875			0.988
No	109 (55.3)	36 (54.5)	73 (55.7)		42 (55.3)	67 (55.4)	
Yes	88 (44.7)	30 (45.5)	58 (44.3)		34 (44.7)	54 (44.6)	
265							

266 Table 5 (Continued)

	T-4-1	Neutralizi	ng Antibody		I		
Characteristics	Total (N=197)	+	-	P	+	-	P
	(N=197)	(N=66)	(N=66) (N=131)		(N=76)	N=76) (N=121)	
Doses of vaccination				<0.001*			<0.001*
One dose	30 (15.2)	2 (3.0)	28 (21.4)		3 (3.9)	27 (22.3)	
Two doses	154 (78.2)	51 (77.3)	103 (78.6)		60 (78.9)	94 (77.7)	
Three doses	13 (6.6)	13 (19.7)	0 (0.0)		13 (17.1)	0 (0.0)	
Inoculation durations, wk				0.009*			<0.001*
<20	8 (4.1)	3 (4.5)	5 (3.8)		7 (9.2)	1 (0.8)	
20-24	22 (11.2)	13 (19.7)	9 (6.9)		14 (18.4)	8 (6.6)	
24-28	50 (25.4)	22 (33.3)	28 (21.4)		25 (32.9)	25 (20.7)	
28-32	61 (31.0)	12 (18.2)	49 (37.4)		14 (18.4)	47 (38.8)	
32-36	38 (19.3)	10 (15.2)	28 (21.4)		12 (15.8)	26 (21.5)	
≥36	18 (9.1)	6 (9.1)	12 (9.2)		4 (5.3)	14 (11.6)	

267 *: *P* < 0.05

3.2 Effects of nutritional supplements on antibody levels

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

To determine the effect of nutritional supplements on antibody levels, multivariate logistic regression analysis was performed. After adjustment for confounding factors such as age, education, vaccine doses, and time since vaccination, we found that there was no significant difference in the positive rates of SARS-CoV-2 neutralizing antibody and IgG antibody according to whether participants took the three nutritional supplements (P > 0.05). Compared with pregnant women who did not take folic acid, the odds ratios (ORs) for the presence of SARS-CoV-2 NAb and IgG antibody in pregnant women who took folic acid were 0.69 (P = 0.282; 95% CI, 0.35-1.35) and 1.31 (P = 0.456; 95% CI, 0.64-2.67), respectively. Compared with pregnant women who did not take iron supplements, the ORs for the presence of NAb and IgG antibody in pregnant women who took iron supplements were 1.22 (P = 0.336; 95% CI, 0.81-1.84) and 1.01 (P = 0.956; 95% CI, 0.66-1.54), respectively. Similarly, the ORs for NAb and IgG antibody were 0.74 (P = 0.125; 95% CI, 0.51-1.08) and 0.97 (P = 0.881; 95% CI, 0.66-1.44) in pregnant women who took DHA compared with those who did not (Table 6).

Table 6 Multivariable logistic regression analysis of Nutritional supplements and antibody positivity.

Characteristics	P	Neutralizing Antibody OR (95%CI)	P	IgG OR (95%CI)
Folic acid				
No take		1.00		1.00
Take	0.282	0.69 (0.35-1.35)	0.456	1.31 (0.64-2.67)
Chalybeate				
No take		1.00		1.00
Take	0.336	1.22 (0.81-1.84)	0.956	1.01 (0.66-1.54)
DHA				
No take		1.00		1.00
Take	0.125	0.74 (0.51-1.08)	0.881	0.97 (0.66-1.41)

Adjusted for age, BMI, education, number of exercises per week, adverse events, inoculation durations, doses of vaccination.

4 Discussion

The present study showed no association between supplementation during pregnancy and antibody levels in pregnant women who received inactivated SARS-CoV-2 vaccines.

During the COVID-19 pandemic, vaccination has proven to be the most effective control measure in establishing an immune barrier and reducing the rate of severe disease. Although pregnant women were not included in the clinical trials of COVID-19 vaccines before market release, they face higher severity and mortality rates once infected. Therefore, there is a greater need for pregnant women to get vaccinated in order to protect themselves and their fetuses. With more attention paid to pregnant women's health and nutrient intake, nutritional supplements have been ubiquitously used during pregnancy. Because the development and maintenance of immune cells

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

that support vaccine response depend on a sufficient supply of nutrients, the role of nutritional supplements in immune response to vaccines has drawn increasing attention. Clinical studies show that low plasma DHA levels during fetal development are associated with cognitive and behavioral disorders²². The brain needs DHA supplementation during development of the nervous system. DHA supplementation during pregnancy can increase fetal birth weight, reduce the risk of preterm birth and low birth weight, and also have a positive effect on infant attention regulation^{23,24}. Thus it is necessary to pay attention to DHA intake during pregnancy. In a double-blind, placebo-controlled, randomized trial, children of mothers who took DHA supplements during pregnancy were found to have better problem-solving abilities at age 9 y than those who did not²⁵. Taking DHA supplements also improves the health of pregnant women. A randomized controlled trial of low-income African American women showed that pregnant women who received DHA supplementation reported lower levels of stress and had lower levels of stress hormones²⁶. The results of this research indicate that DHA intake is not associated with pregnant women's antibody levels. Folic acid is essential for DNA and protein synthesis and also plays a crucial role in adaptive immune responses²⁷. Pregnancy is a common cause of folic acid deficiency, which can lead to pregnancy complications and affect the growth and development of children, including pregnancy-induced hypertension, increased risk of miscarriage, neural tube defects, cleft lip and palate. Studies have shown that folic acid supplementation during pregnancy may help reduce the risk of prenatal depression and have beneficial effects on fertility^{28,29}. The Centers for Disease Control and Prevention

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

in the USA recommends that women of childbearing age supplement with 400 µg/d of folic acid daily, beginning at least four weeks before conception and continuing through the first three months of pregnancy. In terms of vaccine immune response, taking folic acid during pregnancy increases the persistence of hepatitis B surface antibodies in the fetus³⁰. Our study showed that taking folic acid is not associated with pregnant women's antibody levels. This is because the aforementioned study explored the relationship between folic acid supplements during pregnancy and the immune persistence of antibodies in the fetus, which differs from the focus of our research. Other confounding factors in this study, such as vaccine dosage and income level, may also contribute to this result. In a cluster randomized clinical trial conducted in Niger, the effect of prenatal nutritional supplements on immune responses to oral attenuated rotavirus vaccine was assessed. The results showed that in this low-income country, the types of prenatal nutritional supplements have no effect on immune reactions³¹. Iron, an essential nutrient, plays a significant role in the immune system³². Every cell and organ system in the human body requires iron for normal development and metabolic function. Iron deficiency often causes anemia during pregnancy, severely threatening the health of pregnant women and fetuses and increasing the incidence of adverse pregnancy outcomes. A meta-analysis showed a dose-response relationship between iron and birth weight, where before reaching a dose of 66mg, every additional 10mg/day of iron supplementation can increase birth weight by 15.1g, reduce the risk of low birth weight by 3%, and decrease the rate of anemia by 12%³³. In a birth cohort study, anemia and iron deficiency during babies' vaccination were found to predict a

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

decrease in response to vaccines against diphtheria, whooping cough, and pneumococcus. Iron supplementation increases antibody affinity and seroconversion of the measles vaccine³⁴. Our study showed that taking iron supplements does not affect antibody levels in pregnant women. This may be because the efficacies of various vaccines differ across populations, age groups, and environmental conditions. Iron, folic acid and DHA are important nutrient supplements during pregnancy. A cross-sectional study conducted in China found that the use rate of folic acid was the highest (81.7%) and the most stable among various nutrient supplements³⁵. Women of childbearing age and pregnant women are at risk of developing anemia, and iron deficiency is the most recognized risk factor for this condition. Pregnancy poses a significant risk of iron deficiency for women. Iron requirements are greatly increased compared to the non-pregnant state. Adequate iron during pregnancy leads to better pregnancy outcomes for both mother and child. During pregnancy, DHA is transferred in large quantities to the fetus through the placenta. The maternal DHA nutritional status directly affects the fetal DHA nutritional status, which in turn affects fetal development. This research is a cross-sectional study based on real-world data, differing from the aforementioned studies in terms of research design. Furthermore, differences in research subjects and vaccines can also cause different results. For example, the mechanisms of vaccines may vary between the immune systems of fetuses and pregnant women, thereby producing inconsistent immune responses. Finally, readjusting an established immune system may require additional intervention beyond nutritional

supplements, and the most effective supplement has not been identified.

We acknowledge some limitations in present study. Because the data on supplements taken by pregnant women were based on self-report, there may have been some recall bias. Another drawback is the lack of survey information on nutrient intake among pregnant women, which could lead to imprecise results. In the future, we may consider measuring the baseline levels of nutritional supplements in the first trimester and evaluating the effects of nutrient supplements such as vitamin D, calcium, and zinc on the immune levels of pregnant women, to provide more effective recommendations on nutrient intake for pregnant women.

5 Conclusions

Nutritional supplementation with folic acid, iron, and DHA during pregnancy was not associated with antibody levels in pregnant women who received inactivated SARS-CoV-2 vaccines.

Acknowledgments

We thank all pregnant women who took part in this survey and the health care workers who helped us.

References

[1] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. (2020) May 14;55(5):2000547. doi: 10.1183/13993003.00547-2020.

- [2] Skirrow H, Barnett S, Bell S, Riaposova L, Mounier-Jack S, Kampmann B, et al.
- Women's views on accepting COVID-19 vaccination during and after pregnancy,
- and for their babies: a multi-methods study in the UK. BMC Pregnancy Childbirth.
- 414 (2022) Jan 14;22(1):33. doi: 10.1186/s12884-021-04321-3.
- 415 [3] Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients
- with immune-mediated inflammatory disease: Review of available evidence. J Am
- 417 Acad Dermatol.(2021)Nov;85(5):1274-1284.doi: 10.1016/j.jaad.2021.07.054.
- 418 [4] Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-
- 419 19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and
- 420 escape. Nat Rev Immunol. (2021) Oct;21(10):626-636. doi: 10.1038/s41577-021-
- 421 00592-1.
- 422 [5] Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, et al.
- 423 COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients,
- and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview
- of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine
- 426 Efficacy and Safety. Drug Saf. (2021) Dec;44(12):1247-1269.
- 427 doi:10.1007/s40264-021-01131-6.
- 428 [6] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
- Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. (2021) Feb
- 430 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.
- 431 [7] Gorun F, Motoi S, Malita D, Navolan DB, Nemescu D, Olariu TR, et al.
- Cytomegalovirus seroprevalence in pregnant women in the western region of
- Romania: A large-scale study. Exp Ther Med. (2020) Sep;20(3):2439-2443. doi:
- 434 10.3892/etm.2020.8945.
- 435 [8] Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal
- and Neonatal Morbidity and Mortality Among Pregnant Women With and
- Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study.
- 438 JAMA Pediatr. (2021) Aug 1;175(8):817-826. doi:
- 439 10.1001/jamapediatrics.2021.1050. Erratum in: JAMA Pediatr. 2022 Jan

- 440 1;176(1):104.
- [9] Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al.
- Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2
- Infection in Pregnant Women. JAMA. (2021) Aug 24;326(8):728-735. doi:
- 444 10.1001/jama.2021.11035.
- 445 [10] Maggini S, Pierre A, Calder PC. Immune Function and Micronutrient
- Requirements Change over the Life Course. Nutrients. (2018) Oct 17;10(10):1531.
- doi: 10.3390/nu10101531.
- [11] Junaid K, Ejaz H, Abdalla AE, Abosalif KOA, Ullah MI, Yasmeen H, et al.
- Effective Immune Functions of Micronutrients against SARS-CoV-2. Nutrients.
- 450 (2020) Sep 29;12(10):2992. doi: 10.3390/nu12102992.
- [12] Iddir M, Brito A, Dingeo G, Fernandez Del Campo SS, Samouda H, La Frano MR,
- Bohn T. Strengthening the Immune System and Reducing Inflammation and
- Oxidative Stress through Diet and Nutrition: Considerations during the COVID-
- 454 19Crisis. Nutrients. (2020) May27;12(6):1562. doi: 10.3390/nu12061562.
- 455 [13] Samartin S., Chandra R. Obesity, overnutrition and the immune system. Nutr. Res.
- 456 (2001);21:243–262. doi: 10.1016/S0271-5317(00)00255-4.
- 457 [14] Brown B, Wright C. Safety and efficacy of supplements in pregnancy. Nutr Rev.
- 458 (2020) Oct 1;78(10):813-826. doi: 10.1093/nutrit/nuz101.
- 459 [15] Bulloch RE, Lovell AL, Jordan VMB, et al. Maternal folic acid supplementation
- 460 for the prevention of preeclampsia: a systematic review and meta-
- analysis. Paediatr Perinat Epidemiol. (2018);32:346–357.
- [16] Zamora TG, Guiang SF 3rd, Widness JA, Georgieff MK. Iron is prioritized to red
- blood cells over the brain in phlebotomized anemic newborn lambs. Pediatr Res.
- 464 (2016) Jun;79(6):922-8. doi: 10.1038/pr.2016.20.
- [17] Petry N, Olofin I, Hurrell RF, Boy E, Wirth JP, Moursi M, et al. The Proportion
- of Anemia Associated with Iron Deficiency in Low, Medium, and High Human
- Development Index Countries: A Systematic Analysis of National Surveys.
- Nutrients. (2016) Nov 2;8(11):693. doi: 10.3390/nu8110693.

- [18] Figueiredo ACMG, Gomes-Filho IS, Silva RB, Pereira PPS, Mata FAFD, Lyrio
- 470 AO, et al. Maternal Anemia and Low Birth Weight: A Systematic Review and
- 471 Meta-Analysis. Nutrients. (2018) May 12;10(5):601. doi: 10.3390/nu10050601.
- [19] Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, et al. Maternal
- anemia and risk of adverse birth and health outcomes in low- and middle-income
- countries: systematic review and meta-analysis. Am J Clin Nutr.
- 475 (2016) Feb; 103(2): 495-504. doi: 10.3945/ajcn.115.107896.
- 476 [20] Shulkin M, Pimpin L, Bellinger D, Kranz S, Fawzi W, Duggan C, et al. n-3 Fatty
- Acid Supplementation in Mothers, Preterm Infants, and Term Infants and
- Childhood Psychomotor and Visual Development: A Systematic Review and
- 479 Meta-Analysis. J Nutr. (2018) Mar 1;148(3):409-418. doi: 10.1093/jn/nxx031.
- 480 [21] Larqué E, Gil-Sánchez A, Prieto-Sánchez MT, Koletzko B. Omega 3 fatty acids,
- gestation and pregnancy outcomes. Br J Nutr. (2012) Jun;107 Suppl 2:S77-84. doi:
- 482 10.1017/S0007114512001481.
- 483 [22] Jouanne M, Oddoux S, Noël A, Voisin-Chiret AS. Nutrient Requirements during
- Pregnancy and Lactation. Nutrients. (2021) Feb 21;13(2):692. doi:
- 485 10.3390/nu13020692.
- 486 [23] Vinding RK, Stokholm J, Sevelsted A, Chawes BL, Bønnelykke K, Barman M, et
- al. Fish Oil Supplementation in Pregnancy Increases Gestational Age, Size for
- Gestational Age, and Birth Weight in Infants: A Randomized Controlled Trial. J
- Nutr. (2019) Apr 1;149(4):628-634. doi: 10.1093/jn/nxy204.
- 490 [24] Colombo J, Gustafson KM, Gajewski BJ, Shaddy DJ, Kerling EH, Thodosoff JM,
- et al. Prenatal DHA supplementation and infant attention. Pediatr Res. (2016)
- 492 Nov;80(5):656-662. doi: 10.1038/pr.2016.134.
- 493 [25] Judge MP, Harel O, Lammi-Keefe CJ. Maternal consumption of a
- docosahexaenoic acid-containing functional food during pregnancy: benefit for
- infant performance on problem-solving but not on recognition memory tasks at
- age 9 mo. Am J Clin Nutr. (2007) Jun;85(6):1572-7. doi: 10.1093/ajcn/85.6.1572.
- 497 [26] Keenan K, Hipwell AE, Bortner J, Hoffmann A, McAloon R. Association between

- fatty acid supplementation and prenatal stress in African Americans: a randomized
- 499 controlled trial. Obstet Gynecol. (2014) Dec;124(6):1080-1087. doi:
- 500 10.1097/AOG.000000000000559.
- [27] Kumar P, Kumar M, Bedi O, Gupta M, Kumar S, Jaiswal G, et al. Role of vitamins
- and minerals as immunity boosters in COVID-19. Inflammopharmacology. (2021)
- 503 Aug;29(4):1001-1016. doi: 10.1007/s10787-021-00826-7.
- 504 [28] Jin X, Cheng Z, Yu X, Tao Q, Huang R, Wang S. Continuous supplementation of
- folic acid in pregnancy and the risk of perinatal depression-A meta-analysis. J
- Affect Disord. (2022) Apr 1;302:258-272. doi: 10.1016/j.jad.2022.01.
- 507 [29] Gaskins AJ, Chavarro JE. Diet and fertility: a review. Am J Obstet Gynecol. (2018)
- 508 Apr;218(4):379-389. doi: 10.1016/j.ajog.2017.08.010.
- 509 [30] Zhao X, Pang X, Wang F, Cui F, Wang L, Zhang W. Maternal folic acid
- supplementation and antibody persistence 5 years after hepatitis B vaccination
- among infants. Hum Vaccin Immunother. (2018);14(10):2478-2484. doi:
- 512 10.1080/21645515.2018.1482168.
- [31] Sanaka S, Garba S, Plikaytis B, Malone McNeal M, Guindo O, Langendorf C, et
- al. Immunogenicity of an oral rotavirus vaccine administered with prenatal
- nutritional support in Niger: A cluster randomized clinical trial. PLoS Med. (2021)
- Aug 10;18(8):e1003720. doi: 10.1371/journal.pmed.
- 517 [32] Kehl-Fie TE, Skaar EP. Nutritional immunity beyond iron: a role for manganese
- and zinc. Curr Opin Chem Biol. (2010) Apr;14(2):218-24. doi:
- 519 10.1016/j.cbpa.2009.11.008.
- 520 [33] Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Nutrition
- Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of
- adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. (2013)
- 523 Jun 21;346:f3443. doi: 10.1136/bmj.f3443.
- 524 [34] Toffel NU, Uyoga MA, Mutuku FM, Frost JN, Mwasi E, Paganini D, et al. Iron
- Deficiency Anemia at Time of Vaccination Predicts Decreased Vaccine Response
- and Iron Supplementation at Time of Vaccination Increases Humoral Vaccine

Response: A Birth Cohort Study and a Randomized Trial Follow-Up Study in Kenyan Infants. Front Immunol. (2020)Jul 13;11:1313. doi: 10.3389/fimmu.2020.01313. [35] Chatterjee R, Shand A, Nassar N, Walls M, Khambalia AZ. Iron supplement use in pregnancy - Are the right women taking the right amount? Clin Nutr. (2016) Jun;35(3):741-7. doi: 10.1016/j.clnu.2015.05.014.